Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents

Inclusion Criteria: * Healthy men or women aged from 3 years to \< 19 years * Subjects were born after full term pregnancy (37 weeks) * Woman of childbearing potential must have a negative result from Urine Human Chorionic Gonadotropin(HCG) test at the screening visit. * Voluntary written informed consent was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 7 years of age) Exclusion Criteria: * Subject with a known serious allergy reaction after influenza vaccination or to any component vaccine including eggs * Subject who had received an influenza vaccine within the last 6 months * Subject who has, or has a family history of, an immune system disorder including immune deficiency disease * Subject with a history of Guillain-Barre syndrome * Subject with Down's syndrome or cytogenetic disorders. * Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial * Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection * Subject who had an acute fever with body temperature \> 38.0 Cº within 72 hours prior to administration of the study vaccine * Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period. * Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine * Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study. * Subject who had participated in another experimental study within 28 days prior to administration of the study vaccine * Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.